- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00982904
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The present study is designed to obtain safety, tolerability and PK data after single and multiple oral administration of increasing doses of fexinidazole in healthy male sub-Saharan African subjects. This study will also assess the relative bioavailability of fexinidazole administered as a tablet in comparison with oral suspension, and to assess the impact of concomitant food intake on the relative bioavailability of fexinidazole after single oral dose administration.
The study will be divided in 3 successive parts. Study Part I will be a randomized, double-blind, placebo-controlled, single ascending dose study with fexinidazole administered as an oral suspension.
Study Part II will be a comparative bioavailability study of a fexinidazole tablet vs. the oral suspension and assessment of food effect, according to a three-way cross-over design. Clinical part will be conducted in open conditions and bioanalysis in blind conditions.
Study Part III will be a randomized, double-blind, placebo-controlled, multiple ascending dose study with fexinidazole administered either as an oral suspension or as a tablet, depending on Part II results. Dosage regimen will be either q.d. or b.i.d., depending on Part I and Part II results for the unchanged drug and the metabolites. Treatment duration will be 14 days.
Bioanalysis will be performed in open conditions for Study Part I and Study Part III.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- SGS Aster
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All subjects to be of sub-Saharan African origins with both parents of sub-Saharan African origins too,
- Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2) from 18 to 28 kg/m2 at screening,
- Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study,
- Provision of written informed consent to participate as shown by a signature on the volunteer consent form,
- Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers.
- Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator.
- Registered with the French Social Security in agreement with the French law on biomedical experimentation.
Exclusion Criteria:
- Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection,
- Who previously received fexinidazole,
- With any clinically significant abnormality following review of pre-study laboratory tests(ASAT, ALAT and ALP must be within normal ranges), vital signs, full physical examination and ECG,
- Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health,
- Who forfeit their freedom by administrative or legal award or who were under guardianship,
- Unwilling to give their informed consent,
- Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti- HCV antibodies
- Who have a history of allergy, intolerance or photosensitivity to any drug,
- Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug,
- Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol),
- Who drink more than 8 cups daily of beverage containing caffeine,
- Who have a positive laboratory test for urine drug screening
- Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study,
- Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration,
- Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study,
- Who participated to any clinical trial with an investigational drug in the past 3 months preceding study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Fexinidazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurence of adverse events (AEs)
Time Frame: 8 to 37 days, depending on the part of the study
|
8 to 37 days, depending on the part of the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic : measure of blood and urine concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine AUC0-t and Cmax values, for all dose levels
Time Frame: pre-dose, and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 48, 72, 96, 120, 144 and 168 h post-dose
|
pre-dose, and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 48, 72, 96, 120, 144 and 168 h post-dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lionel Hovsepian, MD, SGS Aster
- Study Chair: Nathalie Strub-Wourgaft, MD, Drugs for Neglected Diseases initiative
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DNDiFEX001
Plan for Individual participant data (IPD)
Study Data/Documents
-
Publication of results
Information comments: Publication of results
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human African Trypanosomiasis
-
Drugs for Neglected DiseasesInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsNot yet recruitingHuman African Trypanosomiasis
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Institute of Tropical Medicine, BelgiumCompletedHuman African TrypanosomiasisCongo, The Democratic Republic of the
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesSwiss Tropical & Public Health Institute; Ministry of Public Health, Democratic...Completed
-
Drugs for Neglected DiseasesCompletedSleeping Sickness | Human African Trypanosomiasis (HAT)Central African Republic, Congo, The Democratic Republic of the, Congo
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | African Trypanosomiases | West African Sleeping Sickness | Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, GambienseCongo, The Democratic Republic of the, Côte D'Ivoire, Burkina Faso
-
Institut de Recherche pour le DeveloppementFoundation for Innovative New Diagnostics; Programme National de lutte contre... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | West African Sleeping SicknessCôte D'Ivoire, Guinea
-
Foundation for Innovative New Diagnostics, SwitzerlandMakerere University; Ministry of Public Health, Democratic Republic of the...WithdrawnHuman African Trypanosomiasis
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedTrypanosoma Brucei Gambiense; Infection | Sleeping Sickness; West African | African Trypanosomiases | West African; TrypanosomiasisCongo, The Democratic Republic of the, Côte D'Ivoire, Guinea
Clinical Trials on Fexinidazole/Placebo
-
Drugs for Neglected DiseasesTerminated
-
Drugs for Neglected DiseasesCompletedChagas' Disease (Chronic) NosSpain
-
SanofiCompletedHepatic Function AbnormalBulgaria, France
-
Drugs for Neglected DiseasesSanofiCompletedPK in Healthy VolunteersFrance
-
Drugs for Neglected DiseasesCompletedTrypanosomiasis, AfricanFrance
-
Drugs for Neglected DiseasesSanofiCompletedTrypanosomiasis, African | Sleeping Sickness | Trypanosomiasis; GambianCongo, The Democratic Republic of the, Guinea
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesUnknownChagas Disease | Trypanosomiasis, South American | South American Trypanosomiasis | Disease, ChagasBolivia
-
Drugs for Neglected DiseasesEuropean and Developing Countries Clinical Trials Partnership (EDCTP)CompletedTrypanosoma Brucei Rhodesiense; InfectionMalawi, Uganda
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the